PHK
TNGX icon

Point72 Hong Kong’s Tango Therapeutics TNGX Stock Holding History

Point72 Hong Kong’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,257
Closed -$15K – 1545
2022
Q3 		$15K Buy
+4,257
New +$18.2K ﹤0.01% 1669

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Point72 Hong Kong's TNGX Position: Q4 2022 in Review

Point72 Hong Kong sold out of Tango Therapeutics (TNGX) in Q4 2022, closing a stake of 4,257 shares — an estimated $15K sold.

Point72 Hong Kong first reported a position in TNGX in Q3 2022 and held it in 1 quarter. The position peaked at $15K in Q3 2022. 82 funds tracked by Wall St. Rank hold TNGX as of Q4 2022.

  • Point72 Hong Kong reported no remaining Tango Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 4,257 Tango Therapeutics shares in Q4 2022, an estimated $15K.
  • Point72 Hong Kong first reported a position in Tango Therapeutics in Q3 2022 and held it in 1 quarter.
  • Point72 Hong Kong's Tango Therapeutics position peaked at $15K in Q3 2022.
  • 82 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.